Skip to main content

Table 3 Univariate and multivariate Cox regression analysis for biochemical progression-free survival in patients undergoing PSMA PET/CT-directed radiotherapy or surgery

From: Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy

Characteristics

Univariate analysis

Multivariate analysis

HR

95% CI

Pa

HR

95% CI

Pa

Age at diagnosis

0.99

0.93, 1.06

0.80

-

-

-

Initial T stage

  

0.90

   

 p/cT1

1.00

Reference

 

-

-

-

 p/cT2

0.75

0.15, 3.77

0.73

-

-

-

 p/cT3

0.93

0.21, 4.13

0.92

-

-

-

Initial Gleason Score

1.06

0.69, 1.63

0.77

-

-

-

Adjuvant ADT

  

0.10

   

 No

1.00

Reference

    

 Yes

1.99

0.83, 4.76

0.12

-

-

-

Age at PET/CT

0.97

0.92, 1.03

0.37

-

-

-

PSA at PET/CT

1.06

0.95, 1.18

0.27

-

-

-

PSA-DT at PET/CT

1.01

0.99, 1.03

0.29

-

-

-

Number of lesions

  

0.02

   

 1

1.00

Reference

 

1.00

Reference

 

 2

1.80

0.63, 5.14

0.27

3.42

1.04, 11.25

0.04

 3–5

4.07

1.41, 11.77

0.009

5.04

1.65, 15.42

0.005

Site of lesions

  

0.002

   

 Local

1.00

Reference

 

1.00

Reference

 

 Pelvic nodal

1.89

0.41, 8.72

0.41

1.13

0.23, 5.48

0.88

 Distant

6.67

1.45, 30.63

0.01

6.60

1.39, 31.29

0.02

TLG sum

0.99

0.99, 1.01

0.86

-

-

-

SULmax sum

1.00

0.97, 1.03

0.96

-

-

-

MTV sum

0.97

0.89, 1.06

0.54

-

-

-

  1. HR hazard ratio, CI confidence interval, ADT androgen deprivation therapy, PSA prostate-specific antigen, PSA-DT prostate-specific antigen doubling time, TLG total lesion glycolysis, SULmax maximum standardized uptake value normalized to lean body mass, MTV metabolic tumor volume
  2. aBased on Cox proportional hazards model
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us